Page 16 - Shai Biran News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shai biran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shai Biran Today - Breaking & Trending Today

Molecular Partners AG: Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors


Molecular Partners AG: Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /
March 11, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin
® therapeutics, today
announced the nomination of Agnete Fredriksen, Ph.D., to the Company s Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.
We are pleased to propose Agnete for election to our Board of Directors during a time of growth and development for Molecular Partners, as we lay the foundations for an infectious diseases portfolio and new technologies for next-generation cancer immunotherapies to fruition, said Bill Burns, chairman of the Molecular Partners Board of Directors. We look forward to benefiting from her breadth of expertise across our deepening portfolio as we continue to expand th ....

Shai Biran , Seth Lewis , Thomas Schneckenburger , Bill Burns , Agnete Fredriksen , Company Board Of Directors , Institute Of Immunology , Company On Twitter At Molecularprtnrs , Rikshospitalet Medical Center , Molecular Partners , General Meeting , Molecular Partners Board , ஷாய் பிரன் , சேதி லெவிஸ் , ர சி து தீக்காயங்கள் , நிறுவனம் பலகை ஆஃப் இயக்குநர்கள் , நிறுவனம் ஆஃப் நோயெதிர்ப்பு , மூலக்கூறு கூட்டாளர்கள் , ஜநரல் சந்தித்தல் , மூலக்கூறு கூட்டாளர்கள் பலகை ,

Molecular Partners AG: Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting


(2)
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE /
March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company s immunotherapy programs at the American Academy for Cancer Research (AACR) Virtual Annual Meeting running April 10-15, 2021.
The accepted research describes multiple aspects of validation for the unique mechanisms of these therapies in development for treating a wide range of tumor types.
Accepted abstract titles include:
MP0317 (targeting CD40 and FAP)
MP0317, a FAPxCD40 targeting multi-specific DARPin® therapeutic, drives immune activation and leads to macrophage repolarization in vitro and ex vivo ....

United States , Shai Biran , Prodrug Darpin , Seth Lewis , Thomas Schneckenburger , American Academy For Cancer Research , Company On Twitter At Molecularprtnrs , American Academy , Cancer Research , Virtual Annual Meeting , Molecular Partner , Molecular Partners , ஒன்றுபட்டது மாநிலங்களில் , ஷாய் பிரன் , சேதி லெவிஸ் , அமெரிக்கன் கலைக்கழகம் க்கு புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் கலைக்கழகம் , புற்றுநோய் ஆராய்ச்சி , மெய்நிகர் ஆண்டு சந்தித்தல் , மூலக்கூறு கூட்டாளர் , மூலக்கூறு கூட்டாளர்கள் , நோயெதிர்ப்பு சிகிச்சை ,